Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services
FDA, U.S. Food and Drug Administration
U.S. Food & Drug Administration
 
  • A to Z Index
  • Follow FDA
  • FDA Voice Blog
Search
 
Most Popular Searches
 
  • Home
  • Food
  • Drugs
  • Medical Devices
  • Vaccines, Blood & Biologics
  • Animal & Veterinary
  • Cosmetics
  • Radiation-Emitting Products
  • Tobacco Products
 

Import Alert 66-43

  • Print
  • Share
  • E-mail
  • FDA Home
  • Import Program
  • Import Alerts
  • Imports Alerts by Number
  • Import Alert
-

(Note: This import alert represents the Agency's current guidance to FDA field personnel regarding the manufacturer(s) and/or products(s) at issue. It does not create or confer any rights for or on any person, and does not operate to bind FDA or the public).

Import Alert # 66-43
Published Date: 11/29/2011
Type: DWPE
Import Alert Name:
"Detention Without Physical Examination of THA" (Investigational New Drug)"

Reason for Alert:
Although Alzheimer's disease is clearly a serious disease, the Commissioner stated at a July 28, 1988, meeting that FDA would not exercise its discretion to allow patients to import "THA" for their personal use under the newly instituted mail import policy. This is because "THA" is known to be a potent hepatotoxin and widespread exposure to the drug could result in many cases of serious liver injury. We have been advised by the Division of Neurological Drug Products that a problem exists in the recruitment of people for these active IND's because of the large amounts of "THA" currently being imported illegally.

Guidance:
Districts may detain, without physical examination, all shipments of the unapproved investigational new drug, "THA" to determine if it is covered by a currently active IND.

The following is a list of other names under which the drug may be entering the country:

* Tetrahydroaminoacridine
* 1,2,3,4 Tetrahydro-5 Aminoacridine
* 5-Amino-1, 2, 3,4 Tetrahydroacridine
* 1,2,3,4 tetrahydro-9-Acridinamine
* 9-Amino-1,2,3,4 Tetrahydroacridine
* Tacrine
* Robotal

Product Description:
THA (tetrahydroaminoacridine)

Charge:
"The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be a new drug within the meaning of 201(p), without an approved new drug application pursuant to Section 505(a)."

OASIS charge code - UNAPPROVED

Countries

MULTIPLE COUNTRIES (PODS ONLY)
(66 - - - --) Human and Animal Drugs
Notes:THA
-
-

Links on this page:

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.


  • Accessibility
  • Contact FDA
  • Careers
  • FDA Basics
  • FOIA
  • No Fear Act
  • Site Map
  • Transparency
  • Website Policies
FDA
U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)
Email FDA
  • USA.gov
  • E-mail
  • RSS
  • Twitter
  • Facebook
  • YouTube
  • Flickr
  • For Government
  • For Press
  • Combination Products
  • Advisory Committees
  • Science & Research
  • Regulatory Information
  • Safety
  • Emergency Preparedness
  • International Programs
  • News & Events
  • Training and Continuing Education
  • Inspections/Compliance
  • State & Local Officials
  • Consumers
  • Industry
  • Health Professionals
U.S. Department of Health & Human Services
 

Links on this page: